IGC Pharma hits 146-patient enrollment target in Phase 2 CALMA trial for Alzheimer’s agitation drug IGC-AD1

IGC Pharma, Inc.

IGC Pharma, Inc.

IGC

0.00
  • IGC Pharma hit its Phase 2 CALMA enrollment target, randomizing 146 patients for IGC-AD1 in Alzheimer’s-related agitation.
  • No trial results have been presented; topline analysis is planned following limited over-enrollment and database work.
  • The update signals the study is moving into its final stage, positioning the program for a near-term readout that could guide next-step development.
  • Management is extending enrollment modestly to offset attrition and support a more reliable evaluable dataset for the primary analysis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606110830ACCESSWRNAPR_____1175965) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.